B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.
B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 9, 11, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 2 molecules, respectively.
B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
B-Cell Chronic Lymphocytic Leukemia - Overview 8
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development 27
AB Science SA 27
Aduro BioTech Inc 27
AstraZeneca Plc 28
Bayer AG 28
BioInvent International AB 29
Celgene Corp 29
Cell Source Inc 30
Cellectis SA 30
Chugai Pharmaceutical Co Ltd 30
Dynavax Technologies Corp 31
Elsalys Biotech SAS 31
iDD biotech SAS 32
Immunomedics Inc 32
Juno Therapeutics Inc 33
Lymphocyte Activation Technologies SA 33
MEI Pharma Inc 33
Millennium Pharmaceuticals Inc 34
Molecular Templates Inc 34
Novartis AG 35
Noxxon Pharma AG 35
Ono Pharmaceutical Co Ltd 35
Portola Pharmaceuticals Inc 36
Regeneron Pharmaceuticals Inc 36
Samumed LLC 37
Sunesis Pharmaceuticals Inc 37
TheraMAB LLC 38
Unum Therapeutics Inc 38
Xencor Inc 39
B-Cell Chronic Lymphocytic Leukemia - Drug Profiles 40
202-b - Drug Profile 40
2X-121 - Drug Profile 42
AB-8779 - Drug Profile 45
alemtuzumab biosimilar - Drug Profile 46
alisertib - Drug Profile 47
Aurixim - Drug Profile 53
AZD-4573 - Drug Profile 54
BI-1206 - Drug Profile 55
BION-1301 - Drug Profile 57
Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 59
Cellular Immunotherapy for Hematological Malignancies - Drug Profile 60
Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile 61
Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile 64
Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 65
Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile 66
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 67
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 68
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 69
cerdulatinib - Drug Profile 70
copanlisib hydrochloride - Drug Profile 75
DTRMWXHS-12 - Drug Profile 82
ELB-021 - Drug Profile 83
IDD-001 - Drug Profile 84
IDD-002 - Drug Profile 85
lenalidomide - Drug Profile 86
ME-401 - Drug Profile 104
mRNA ACTR + rituximab - Drug Profile 106
MT-3724 - Drug Profile 108
olaptesed pegol - Drug Profile 111
REGN-1979 - Drug Profile 116
SD-101 - Drug Profile 117
SM-08502 - Drug Profile 122
TAB-08 - Drug Profile 123
tirabrutinib - Drug Profile 126
tisagenlecleucel - Drug Profile 129
tocilizumab - Drug Profile 140
UCART-22 - Drug Profile 151
UCARTCS-1 - Drug Profile 152
vecabrutinib - Drug Profile 153
XmAb-13676 - Drug Profile 156
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects 158
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products 160
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 161
Featured News & Press Releases 161
Appendix 163
Methodology 163
Coverage 163
Secondary Research 163
Primary Research 163
Expert Panel Validation 163
Contact Us 163
Disclaimer 164
List of Tables
List of Tables
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Aduro BioTech Inc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AstraZeneca Plc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Bayer AG, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioInvent International AB, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corp, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cell Source Inc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cellectis SA, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corp, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Elsalys Biotech SAS, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics Inc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Lymphocyte Activation Technologies SA, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by MEI Pharma Inc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Molecular Templates Inc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Novartis AG, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Portola Pharmaceuticals Inc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Samumed LLC, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Sunesis Pharmaceuticals Inc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Unum Therapeutics Inc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Xencor Inc, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2018
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2018 (Contd..1), H1 2018
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H1 2018
List of Figures
List of Figures
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
AB Science SA
Aduro BioTech Inc
AstraZeneca Plc
Bayer AG
BioInvent International AB
Celgene Corp
Cell Source Inc
Cellectis SA
Chugai Pharmaceutical Co Ltd
Dynavax Technologies Corp
Elsalys Biotech SAS
iDD biotech SAS
Immunomedics Inc
Juno Therapeutics Inc
Lymphocyte Activation Technologies SA
MEI Pharma Inc
Millennium Pharmaceuticals Inc
Molecular Templates Inc
Novartis AG
Noxxon Pharma AG
Ono Pharmaceutical Co Ltd
Portola Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Samumed LLC
Sunesis Pharmaceuticals Inc
TheraMAB LLC
Unum Therapeutics Inc
Xencor Inc
Ìý
Ìý
*If Applicable.